SEARCH

SEARCH BY CITATION

References

  • 1
    Choo Q-L, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Nat Acad Sci U S A 1991; 88: 24512455.
  • 2
    Alter MJ, Hadler SC, Judson FN, Mares A, Alexander J, Hu PY, Miller JK, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264: 22312235.
  • 3
    Sherlock S. Chronic hepatitis C. Dis Mon 1994; 40: 122196.
  • 4
    Sharara Al, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996; 125: 658668.
  • 5
    Perrillo RP, Pohl DA, Roodman ST, Tsai CC. Acute non-A, non-B hepatitis with serum sickness-like syndrome and aplastic anemia. JAMA 1981; 245: 494496.
  • 6
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwekk P, Couser WG, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465470.
  • 7
    Casato M, Taliani G, Pucillo LP, Goffredo F, Laganà B, Bonomo L. Cryoglubulinaemia and hepatitis C virus. Lancet 1991; 337: 10471048.
  • 8
    Patel A, Sherlock S, Dusheiko G, Scheuer P, Ellis LA, Ashrafzadeh P. Clinical course and histological correlations in post-transfusion hepatitis C: the Royal Free Hospital experience. Eur J Gastroenterol Hepatol 1991; 3: 491495.
  • 9
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15011506.
  • 10
    Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15: 8291.
  • 11
    Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15: 10131016.
  • 12
    Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 1993; 18: 13001305.
  • 13
    Castillo I, Bartolomé J, Navas S, Gonzalez S, Herrero M, Carreño V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 13421346.
  • 14
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 10501056.
  • 15
    Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16: 489499.
  • 16
    Alton K, Stabinsky Y, Richards R, Ferguson B, Goldstein L, Altrock B, Miller L, et al. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs. In: De MaeyerE, SchellekensH, eds. The Biology of the Interferon System. Amsterdam: Elsevier, 1983: 119128.
  • 17
    Ozes ON, Reiter ZVI, Klein S, Blatt LM, Taylor MW. A comparison of interferon-con l with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992; 12: 5559.
  • 18
    Klein SB, Blatt LM, Taylor MW. Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-α2a. J Interferon Res 1993; 13: 341347.
  • 19
    Schering-Plough package insert. In: Physicians' Desk Reference. New Jersey: Medical Economics Company, Inc., 1997: 25062514.
  • 20
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 10931102.
  • 21
    Simmonds P, Alberti P, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 13211324.
  • 22
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.
  • 23
    Fleiss JL. Statistical Methods for Rates and Proportions. New York: Wiley, 1981.
  • 24
    Alter HJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437455.
  • 25
    Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366371.
  • 26
    Lau JYN, Davis GL, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 15011504.
  • 27
    Takada N, Takase S, Takada A. Effects of genotypes of hepatitis C virus on interferon treatment for chronic type C hepatitis. Gastroenterologia Japonica 1993: 28: 268275.
  • 28
    Kohara M, Tanaka T, Tsukiyama-Kohara K, Tanaka S, Mizokami M, Lau JYN, Hattori N. Hepatitis C virus genotypes 1 and 2 respond to interferon-α with different virologic kinetics. J Infect Dis 1995; 172: 934938.
  • 29
    Diodati G, Bonetti P, Tagger A, Casarin C, Noventa F, Ribero M, Fasola M, et al. Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up. Dig Dis Sci 1994; 39: 24972502.
  • 30
    Dusheiko G, Simmonds P. Sequence variability of hepatitis C virus and its clinical relevance. J Viral Hepat 1994; 1: 315.
  • 31
    Craxi A, Magrin S, Fabiano C, Linea C, Almasio P. Host and viral features in chronic HCV infection: relevance to interferon responsiveness. Res Virol 1995; 146: 273278.
  • 32
    Booth JCL, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon α. Gut 1995; 36: 427432.
  • 33
    Lau JYN, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, Perrillo RP, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995; 171: 281289.
  • 34
    Lau JYN, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian KP, Mizokami M, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 1996; 124: 868876.
  • 35
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 14571462.
  • 36
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778789.
  • 37
    Schiffman ML, Hofmann CM, Luketic VAC, Sanyal AJ, Contos MJ, Mills AS. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology 1996; 24: 2126.
  • 38
    Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety. 1994; 10: 115150.
  • 39
    Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9: 273277.